Review



pe anti ulbp4  (Bio-Techne corporation)


Bioz Verified Symbol Bio-Techne corporation is a verified supplier
Bioz Manufacturer Symbol Bio-Techne corporation manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Bio-Techne corporation pe anti ulbp4
    Pe Anti Ulbp4, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pe+anti+ulbp4/Human+ULBP-4%2FRAET1E+PE-conjugated+Antibody/10__1080_slash_2162402x__2022__2104991-65-66-70
    Average 94 stars, based on 8 article reviews
    pe anti ulbp4 - by Bioz Stars, 2026-09
    94/100 stars

    Images

    Related Articles

    Expressing:

    Article Title: The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology
    Article Snippet: The following mAbs against human molecules were used for FC: APC/Cy7 anti-CD45 (HI30), PerCP/Cy5.5 anti-CD33 (WM53), PerCP/Cy5.5 anti-CD34 (581), FITC anti-CD3 (UCHT1), PE anti-NKG2D (1D11), PE/Cy7 anti-CD44 (IM7), APC anti-CD105 (43A3), BV421 anti-TIM-3 (F38-2E2), BV421 anti-IFN-γ (4S.B3), BV421 anti-CD107a (H4A3) and Alexa Fluor (AF) 488 anti-PD1 (EH12.2H7) from BioLegend; AF488 anti-MICA (159,227), APC anti-MICB (236,511), AF488 anti-ULBP1 (170,818), APC anti-ULBP2/5/6 (165,903), PE anti-ULBP3 (166,510) and PE anti-ULBP4 (709,116) from Biotechne; APC and PE/Cy7 anti-CD56 (N901) from Beckman Coulter; and VF450 and PE/Cy7 anti-CD3 (UCHT1), VF450 anti-CD8a (OKT8) and VF450 anti-CD4 (OKT4) from TONBO.

    Article Title: The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology
    Article Snippet: The following mAbs against human molecules were used for FC: APC/Cy7 anti-CD45 (HI30), PerCP/Cy5.5 anti-CD33 (WM53), PerCP/Cy5.5 anti-CD34 (581), FITC anti-CD3 (UCHT1), PE anti-NKG2D (1D11), PE/Cy7 anti-CD44 (IM7), APC antiCD105 (43A3), BV421 anti-TIM-3 (F38-2E2), BV421 anti-IFN -γ (4S.B3), BV421 anti-CD107a (H4A3) and Alexa Fluor (AF) 488 anti-PD1 (EH12.2H7) from BioLegend; AF488 anti-MICA (159,227), APC anti-MICB (236,511), AF488 anti-ULBP1 (170,818), APC anti-ULBP2/5/6 (165,903), PE anti-ULBP3 (166,510) and PE anti-ULBP4 (709,116) from Biotechne; APC and PE/Cy7 anti-CD56 (N901) from Beckman Coulter; and VF450 and PE/Cy7 anti-CD3 (UCHT1), VF450 anti-CD8a (OKT8) and VF450 anti-CD4 (OKT4) from TONBO.

    Activation Assay:

    Article Title: The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology
    Article Snippet: The following mAbs against human molecules were used for FC: APC/Cy7 anti-CD45 (HI30), PerCP/Cy5.5 anti-CD33 (WM53), PerCP/Cy5.5 anti-CD34 (581), FITC anti-CD3 (UCHT1), PE anti-NKG2D (1D11), PE/Cy7 anti-CD44 (IM7), APC anti-CD105 (43A3), BV421 anti-TIM-3 (F38-2E2), BV421 anti-IFN-γ (4S.B3), BV421 anti-CD107a (H4A3) and Alexa Fluor (AF) 488 anti-PD1 (EH12.2H7) from BioLegend; AF488 anti-MICA (159,227), APC anti-MICB (236,511), AF488 anti-ULBP1 (170,818), APC anti-ULBP2/5/6 (165,903), PE anti-ULBP3 (166,510) and PE anti-ULBP4 (709,116) from Biotechne; APC and PE/Cy7 anti-CD56 (N901) from Beckman Coulter; and VF450 and PE/Cy7 anti-CD3 (UCHT1), VF450 anti-CD8a (OKT8) and VF450 anti-CD4 (OKT4) from TONBO.

    Article Title: The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology
    Article Snippet: The following mAbs against human molecules were used for FC: APC/Cy7 anti-CD45 (HI30), PerCP/Cy5.5 anti-CD33 (WM53), PerCP/Cy5.5 anti-CD34 (581), FITC anti-CD3 (UCHT1), PE anti-NKG2D (1D11), PE/Cy7 anti-CD44 (IM7), APC antiCD105 (43A3), BV421 anti-TIM-3 (F38-2E2), BV421 anti-IFN -γ (4S.B3), BV421 anti-CD107a (H4A3) and Alexa Fluor (AF) 488 anti-PD1 (EH12.2H7) from BioLegend; AF488 anti-MICA (159,227), APC anti-MICB (236,511), AF488 anti-ULBP1 (170,818), APC anti-ULBP2/5/6 (165,903), PE anti-ULBP3 (166,510) and PE anti-ULBP4 (709,116) from Biotechne; APC and PE/Cy7 anti-CD56 (N901) from Beckman Coulter; and VF450 and PE/Cy7 anti-CD3 (UCHT1), VF450 anti-CD8a (OKT8) and VF450 anti-CD4 (OKT4) from TONBO.



    Similar Products

    pe anti ulbp4  (Bio-Techne corporation)
    94
    Bio-Techne corporation pe anti ulbp4
    Pe Anti Ulbp4, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pe+anti+ulbp4/Human+ULBP-4%2FRAET1E+PE-conjugated+Antibody/10__1080_slash_2162402x__2022__2104991-65-66-70
    Average 94 stars, based on 1 article reviews
    pe anti ulbp4 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    pe anti ulbp4  (R&D Systems)
    93
    R&D Systems pe anti ulbp4
    Pe Anti Ulbp4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pe+anti+ulbp4/Human+ULBP-4%2FRAET1E+PE-conjugated+Antibody/pmc11706306-119-107-109
    Average 93 stars, based on 1 article reviews
    pe anti ulbp4 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    anti-ulbp4-pe  (R&D Systems)
    90
    R&D Systems anti-ulbp4-pe
    a. Flow cytometry gating strategy on PDTO cells for analysis of surface staining. Selected cells were gated on single, live cells before quantification of staining signal. b. Histogram representation and count for surface staining of MHC-I, PD-L1, and β2m expression on two PDTO lines B2MWT and B2MKO after IFNγ pre-stimulation. Staining with isotype antibodies for each fluorochrome (PE, APC and FITC) were included as negative control. c. Flow cytometry gating strategy on γδ T cell samples for analysis of intracellular staining to test antitumor reactivity upon PDTO stimulation. Lymphocyte population was further gated on single cells, live and CD3+ cells, γδ TCR+ cells and CD8+ as well as CD8–CD4– cells. Reactivity of the sample was based on IFNγ+ cells of the selected population. d. Histogram representation and count for surface staining of NKG2D ligands MICA/B, ULBP1, ULBP2/5/6, ULBP3, and <t>ULBP4</t> on two PDTO lines B2MWT and B2MKO after IFNγ pre-stimulation. e. Flow cytometry gating strategy on γδ T cell samples for analysis of intracellular staining after stimulation with PDTOs in the presence of NKG2D ligand blocking. Lymphocyte population was further gated on single cells, live and CD3+ cells, followed by γδ TCR+ and CD8+ as well as CD8– cells. Reactivity of final population was based on IFNγ+ or CD107a+ cells.
    Anti Ulbp4 Pe, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pe+anti+ulbp4/ulbp4+fc/bio_rxiv__2021__10__14__464229-213-75-78
    Average 90 stars, based on 1 article reviews
    anti-ulbp4-pe - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    ulbp4  (R&D Systems)
    93
    R&D Systems ulbp4
    a. Flow cytometry gating strategy on PDTO cells for analysis of surface staining. Selected cells were gated on single, live cells before quantification of staining signal. b. Histogram representation and count for surface staining of MHC-I, PD-L1, and β2m expression on two PDTO lines B2MWT and B2MKO after IFNγ pre-stimulation. Staining with isotype antibodies for each fluorochrome (PE, APC and FITC) were included as negative control. c. Flow cytometry gating strategy on γδ T cell samples for analysis of intracellular staining to test antitumor reactivity upon PDTO stimulation. Lymphocyte population was further gated on single cells, live and CD3+ cells, γδ TCR+ cells and CD8+ as well as CD8–CD4– cells. Reactivity of the sample was based on IFNγ+ cells of the selected population. d. Histogram representation and count for surface staining of NKG2D ligands MICA/B, ULBP1, ULBP2/5/6, ULBP3, and <t>ULBP4</t> on two PDTO lines B2MWT and B2MKO after IFNγ pre-stimulation. e. Flow cytometry gating strategy on γδ T cell samples for analysis of intracellular staining after stimulation with PDTOs in the presence of NKG2D ligand blocking. Lymphocyte population was further gated on single cells, live and CD3+ cells, followed by γδ TCR+ and CD8+ as well as CD8– cells. Reactivity of final population was based on IFNγ+ or CD107a+ cells.
    Ulbp4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pe+anti+ulbp4/Human+ULBP-4%2FRAET1E+PE-conjugated+Antibody/pm28771222-137-37-40
    Average 93 stars, based on 1 article reviews
    ulbp4 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    pe-conjugated anti-ulbp4  (R&D Systems)
    90
    R&D Systems pe-conjugated anti-ulbp4
    a. Flow cytometry gating strategy on PDTO cells for analysis of surface staining. Selected cells were gated on single, live cells before quantification of staining signal. b. Histogram representation and count for surface staining of MHC-I, PD-L1, and β2m expression on two PDTO lines B2MWT and B2MKO after IFNγ pre-stimulation. Staining with isotype antibodies for each fluorochrome (PE, APC and FITC) were included as negative control. c. Flow cytometry gating strategy on γδ T cell samples for analysis of intracellular staining to test antitumor reactivity upon PDTO stimulation. Lymphocyte population was further gated on single cells, live and CD3+ cells, γδ TCR+ cells and CD8+ as well as CD8–CD4– cells. Reactivity of the sample was based on IFNγ+ cells of the selected population. d. Histogram representation and count for surface staining of NKG2D ligands MICA/B, ULBP1, ULBP2/5/6, ULBP3, and <t>ULBP4</t> on two PDTO lines B2MWT and B2MKO after IFNγ pre-stimulation. e. Flow cytometry gating strategy on γδ T cell samples for analysis of intracellular staining after stimulation with PDTOs in the presence of NKG2D ligand blocking. Lymphocyte population was further gated on single cells, live and CD3+ cells, followed by γδ TCR+ and CD8+ as well as CD8– cells. Reactivity of final population was based on IFNγ+ or CD107a+ cells.
    Pe Conjugated Anti Ulbp4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pe+anti+ulbp4/ulbp4+fc/pmc04760288-170-29-33
    Average 90 stars, based on 1 article reviews
    pe-conjugated anti-ulbp4 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    pe conjugated anti ulbp4  (R&D Systems)
    93
    R&D Systems pe conjugated anti ulbp4
    a. Flow cytometry gating strategy on PDTO cells for analysis of surface staining. Selected cells were gated on single, live cells before quantification of staining signal. b. Histogram representation and count for surface staining of MHC-I, PD-L1, and β2m expression on two PDTO lines B2MWT and B2MKO after IFNγ pre-stimulation. Staining with isotype antibodies for each fluorochrome (PE, APC and FITC) were included as negative control. c. Flow cytometry gating strategy on γδ T cell samples for analysis of intracellular staining to test antitumor reactivity upon PDTO stimulation. Lymphocyte population was further gated on single cells, live and CD3+ cells, γδ TCR+ cells and CD8+ as well as CD8–CD4– cells. Reactivity of the sample was based on IFNγ+ cells of the selected population. d. Histogram representation and count for surface staining of NKG2D ligands MICA/B, ULBP1, ULBP2/5/6, ULBP3, and <t>ULBP4</t> on two PDTO lines B2MWT and B2MKO after IFNγ pre-stimulation. e. Flow cytometry gating strategy on γδ T cell samples for analysis of intracellular staining after stimulation with PDTOs in the presence of NKG2D ligand blocking. Lymphocyte population was further gated on single cells, live and CD3+ cells, followed by γδ TCR+ and CD8+ as well as CD8– cells. Reactivity of final population was based on IFNγ+ or CD107a+ cells.
    Pe Conjugated Anti Ulbp4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pe+anti+ulbp4/Human+ULBP-4%2FRAET1E+PE-conjugated+Antibody/10__1080_slash_2162402x__2015__1058459-137-29-33
    Average 93 stars, based on 1 article reviews
    pe conjugated anti ulbp4 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    a. Flow cytometry gating strategy on PDTO cells for analysis of surface staining. Selected cells were gated on single, live cells before quantification of staining signal. b. Histogram representation and count for surface staining of MHC-I, PD-L1, and β2m expression on two PDTO lines B2MWT and B2MKO after IFNγ pre-stimulation. Staining with isotype antibodies for each fluorochrome (PE, APC and FITC) were included as negative control. c. Flow cytometry gating strategy on γδ T cell samples for analysis of intracellular staining to test antitumor reactivity upon PDTO stimulation. Lymphocyte population was further gated on single cells, live and CD3+ cells, γδ TCR+ cells and CD8+ as well as CD8–CD4– cells. Reactivity of the sample was based on IFNγ+ cells of the selected population. d. Histogram representation and count for surface staining of NKG2D ligands MICA/B, ULBP1, ULBP2/5/6, ULBP3, and ULBP4 on two PDTO lines B2MWT and B2MKO after IFNγ pre-stimulation. e. Flow cytometry gating strategy on γδ T cell samples for analysis of intracellular staining after stimulation with PDTOs in the presence of NKG2D ligand blocking. Lymphocyte population was further gated on single cells, live and CD3+ cells, followed by γδ TCR+ and CD8+ as well as CD8– cells. Reactivity of final population was based on IFNγ+ or CD107a+ cells.

    Journal: bioRxiv

    Article Title: γδ T cells are effectors of immune checkpoint blockade in mismatch repair-deficient colon cancers with antigen presentation defects

    doi: 10.1101/2021.10.14.464229

    Figure Lengend Snippet: a. Flow cytometry gating strategy on PDTO cells for analysis of surface staining. Selected cells were gated on single, live cells before quantification of staining signal. b. Histogram representation and count for surface staining of MHC-I, PD-L1, and β2m expression on two PDTO lines B2MWT and B2MKO after IFNγ pre-stimulation. Staining with isotype antibodies for each fluorochrome (PE, APC and FITC) were included as negative control. c. Flow cytometry gating strategy on γδ T cell samples for analysis of intracellular staining to test antitumor reactivity upon PDTO stimulation. Lymphocyte population was further gated on single cells, live and CD3+ cells, γδ TCR+ cells and CD8+ as well as CD8–CD4– cells. Reactivity of the sample was based on IFNγ+ cells of the selected population. d. Histogram representation and count for surface staining of NKG2D ligands MICA/B, ULBP1, ULBP2/5/6, ULBP3, and ULBP4 on two PDTO lines B2MWT and B2MKO after IFNγ pre-stimulation. e. Flow cytometry gating strategy on γδ T cell samples for analysis of intracellular staining after stimulation with PDTOs in the presence of NKG2D ligand blocking. Lymphocyte population was further gated on single cells, live and CD3+ cells, followed by γδ TCR+ and CD8+ as well as CD8– cells. Reactivity of final population was based on IFNγ+ or CD107a+ cells.

    Article Snippet: Briefly, cells were incubated with human Fc receptor block (BioLegend) and stained with the different cell surface antibodies (1:10 anti-CD112-PE [clone R2.525, BD Biosciences], 1:10 anti-CD155-PE [clone 300907, R&D Systems], 1:50 anti-CD277/BTN3A1-PE [clone BT3.1, Miltenyi], 1:100 anti-HLA-A,B,C-FITC [clone W6/32, eBioscience], 1:20 anti-HLA-E­BV421 [clone 3D12, BioLegend], 1:20 anti-HLA-G-APC [clone 87G, BioLegend], 1:300 anti-MICA/B-PE [clone 6D4, BioLegend], 1:10 anti-ULBP1-PE [clone 170818, R&D Systems], 1:20 anti-ULBP2/5/6-PE [clone 165903, R&D Systems], 1:20 anti-ULBP3-PE [clone 166510, R&D Systems], or 1:20 anti-ULBP4-PE [clone 709116, R&D Systems] for 45 min at 4°C.

    Techniques: Flow Cytometry, Staining, Expressing, Negative Control, Blocking Assay